TheraRadar
Data updated: May 26, 2026

EMPLICITI (elotuzumab)

SLAMF7-directed Antibody Interactions Trial Activity: Stable 19 active trials
Oncology Approved 2015-11-30

EMPLICITI is indicated for the treatment of Multiple Myeloma.

Source: FDA Label • Bristol-Myers Squibb • SLAMF7-directed Immunostimulatory Antibody
Jump to: Indications Approvals Trials Competitors Similar Safety Patents

How EMPLICITI Works

Elotuzumab is a monoclonal antibody that targets the SLAMF7 protein expressed on myeloma cells and Natural Killer (NK) cells. The drug directly activates NK cells through the SLAMF7 pathway and targets SLAMF7 on myeloma cells to mediate cell killing through antibody-dependent cellular cytotoxicity and phagocytosis. When used in combination with lenalidomide or pomalidomide, the therapy demonstrates enhanced NK cell activation and increased anti-tumor activity.

Source: FDA Label

Development Insights

Bristol-Myers Squibb conducting 9 trials (18%)
26 indications explored (Broad Platform)
→ multiple myeloma (36 trials)
→ plasma cell myeloma (2 trials)
→ recurrent multiple myeloma (2 trials)
5
Indications
--
Phase 3 Trials
2
Priority Reviews
10
Years on Market

Details

Status
Prescription
First Approved
2015-11-30
Patent Cliff
2025

Pro Metrics

Patent cliff and revenue data

Unlock with Pro
Routes
INJECTION
Dosage Forms
INJECTABLE

Companies

Bristol-Myers Squibb
Active Ingredient: ELOTUZUMAB

EMPLICITI Approval History

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
10 FDA actions from 2015 to 2022 · 4 indication expansions
Mar 2022 SUPPL
Efficacy
FDA Letter Label
Oct 2019 SUPPL
Efficacy
FDA Letter Label
Nov 2018 SUPPL Priority
Efficacy
FDA Letter Label

What EMPLICITI Treats

1 indications

EMPLICITI is approved for 1 conditions since its original approval in 2015. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Multiple Myeloma
Source: FDA Label

EMPLICITI Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Indication competitors

10

Same indication, different mechanism — what else might this patient receive?

OZILTUS
AMNEAL PHARMS
2025 4 indic.
BLENREP
GSK
2025 1 indic.
Unlock 8 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

What's emerging in EMPLICITI's indications

See all emerging drugs →

Phase 3 candidates targeting molecules with no FDA-approved drug, in indications EMPLICITI treats. First-in-class if their pivotal trials read out positive.

Tiragolumab MTIG7192A / RG6058 ~ Mixed — Ph3 readout
Hoffmann-La Roche
TIGIT · monoclonal antibody (anti-TIGIT) · 10 Phase 3 trials

Drugs Similar to EMPLICITI

3 of 20

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

APHEXDA
MOTIXAFORTIDE ACETATE
1 shared
AYRMID PHARMA
Shared indications:
Multiple Myeloma
AUKELSO
DENOSUMAB-KYQQ
1 shared
BIOCON BIOLOGICS INC
Shared indications:
Multiple Myeloma
BICNU
CARMUSTINE
1 shared
AVET LIFESCIENCES
Shared indications:
Multiple Myeloma
View all 20 similar drugs Pro
📋

Clinical Trial Registry

51 trials
Trial Sponsor ID Phase Status Title
NCT05002816 2000028918 Ph 1, Ph 2 active not recruiting Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma
NCT05981209 OSU-22207 NCI-2023-05518 Ph 1 active not recruiting Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies
NCT06152575 C1071032 MAGNETISMM-32, 2023-507871-23-00 Ph 3 recruiting MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
NCT02343042 STOMP KCP-330-017 Ph 1, Ph 2 active not recruiting Selinexor and Backbone Treatments of Multiple Myeloma Patients
NCT07555938 CEVOLUTION CO46096 2025-524028-23-00 Ph 3 not yet recruiting Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
NCT01668719 results posted S1211 NCI-2012-01998, PS1211_A12PAMDREVW01 Ph 1, Ph 2 completed S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma
NCT02420860 2014-0729 NCI-2015-00762, 2014-0729 Ph 2 active not recruiting Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
NCT02719613 CA204-185 2016-000037-51 Ph 2 completed Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab
NCT04835129 IMPEDE PRO00041365 Ph 2 active not recruiting Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
NCT06158841 CERVINO M22-574 2023-506668-15-00 Ph 3 recruiting Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT06208150 MonumenTAL-6 64407564MMY3009 64407564MMY3009, 2022-502446-27-00 Ph 3 recruiting A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
NCT03361306 results posted LCI-HEM-MYE-CRD-002 00023493 Ph 2 completed LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple Myeloma
NCT05730036 LINKER-MM3 R5458-ONC-2245 2022-501396-62-00 Ph 3 recruiting A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
NCT04918147 results posted DAIT AIG01 UM1AI144298, NIAID CRMS ID#: 38708 Ph 2 terminated Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)
NCT02718833 15-475 Ph 2 active not recruiting A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma
NCT02969837 results posted IRB16-1138 Ph 2 completed Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma
NCT04517851 2020-0522 NCI-2020-05712, 2020-0522 Ph 2 active not recruiting Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis
NCT03030261 results posted 201701084 CA204-225, PO-CL-MM-PI-008341 Ph 2 active not recruiting Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma
NCT06518551 24-189 Ph 1, Ph 2 recruiting Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
NCT05028348 EMN29 Ph 3 active not recruiting A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma
NCT06785415 MC230812 NCI-2025-00138, 24-010000 Ph 1, Ph 2 recruiting Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma
NCT03713294 results posted MC1884 NCI-2018-02140, MC1884 Ph 2 completed Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients With Refractory Multiple Myeloma
NCT01729091 results posted 2011-0379 NCI-2014-01096, RV-MM-PI-0691 Ph 2 completed Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma
NCT03989414 CC-92480-MM-002 U1111-1233-5619, 2023-505219-19 Ph 1, Ph 2 active not recruiting A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
NCT02375555 results posted 14-453 Ph 2 completed Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM
NCT03000634 204814 Ph 2 withdrawn 2015-09: a Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance Therapy
NCT06232707 ALUMMINATE CA058-1019 2023-509472-42, U1111-1281-8227 Ph 3 withdrawn A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT02843074 results posted SCRI MM61 Ph 2 completed Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients
NCT04614636 FT538-101 Ph 1 terminated FT538 in Subjects With Advanced Hematologic Malignancies
NCT02279394 results posted 14-338 Ph 2 completed E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma
NCT03948035 DSMM XVII 2017-001616-11 Ph 3 active not recruiting Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM
NCT03411031 results posted MCC-19197 NCI-2018-00891 Ph 2 terminated Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide
NCT02726581 CheckMate 602 results posted CA209-602 2015-005699-21 Ph 3 completed An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma
NCT03651128 KarMMa-3 BB2121-MM-003 U1111-1217-9988, 2018-001023-38 Ph 3 active not recruiting Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
NCT02654132 results posted CA204-125 2014-003282-19 Ph 2 completed An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)
NCT03104270 CA204-187 Ph 2 terminated Combination Study for High Risk Multiple Myeloma Patients
NCT02495922 GMMG-HD6 GMMG HD6 Ph 3 completed A Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma
NCT04584307 Immuno-POWER BTCRC-MM19-428 Ph 2 withdrawn Phase II Study of Immunomaintenance Using POmalidomide With Elotuzumab afteR Second Autologous Transplant
NCT02612779 results posted CA204-142 Ph 2 completed A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.
NCT01891643 results posted CA204-006 (Biomarker Substudy) 2010-022445-20 Ph 3 terminated PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy)
NCT03003728 205009 Ph 2 withdrawn 2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT)
NCT03393273 IFM2016-03 P170103 2017-001446-10 Ph 2 withdrawn Elotuzumab in Patients With Multiple Myeloma Before and After Peripheral Stem Cell Autologous Graft
NCT02159365 results posted CA204-112 Ph 2 completed Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients
NCT03168100 206603 Ph 2 withdrawn 2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma
NCT03227432 16-645 Ph 2 withdrawn An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma
NCT03023527 GEM-NIVOPOMDEX Ph 1 terminated Nivolumab Role in the Treatment of Patients With Refractory or Relapse Multiple Myeloma
NCT01478048 results posted CA204-009 2011-002695-16 Ph 2 completed Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
NCT00742560 results posted HuLuc63-1703 2007-006677-83 Ph 2 completed A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple Myeloma
NCT02252263 CA223-028 Ph 1 completed A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
NCT02655458 GCO 15-1275 Ph 1 completed Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma

Showing 50 of 51 trials

🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

ClinicalTrials.gov ↗ Pro

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

EMPLICITI FDA Label Details

Indications & Usage

FDA Label (PDF)

EMPLICITI is indicated for the treatment of Multiple Myeloma.

Track EMPLICITI with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

FDA Approval: BLA761035 → Label: DailyMed → Trials: ClinicalTrials.gov →

Data sourced from official FDA and NIH databases. Click links to verify on original sources.

How We Calculate These Metrics

Trial Activity Stage

Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.

Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.

  • Growth: High proportion of early-phase trials (Phase 1/2), active development
  • Expansion: Significant Phase 3 activity, approaching or pursuing approvals
  • Mature: Substantial Phase 4 post-marketing studies
  • Stable: Mixed phase distribution, steady development
  • Declining: Low active trial ratio, reduced R&D investment